Kenvue Slashes Full-Year Forecast After Q2 Miss On All Fronts

Kenvue (NYSE:KVUE) posted second-quarter results that missed expectations across the board and revised its 2025 outlook lower.

The consumer health company reported adjusted EPS of $0.29, below the $0.35 consensus. Revenue totaled $3.84 billion, missing expectations of $4.18 billion.

The disappointing results led Kenvue to lower its full-year adjusted EPS forecast to $1.00–$1.05, compared to the $1.13 analysts projected. The company had previously forecast EPS around $1.14.

Kenvue now expects net and organic sales to decline in the low single digits for 2025.

Organic sales for the second quarter dropped 4.2% year-over-year. The company attributed the decline to adverse pricing, lower volumes, weak seasonal performance in allergy and sun care categories in North America, inventory adjustments, and shipment timing shifts in China.